How can my 53-year-old mom manage her small-cell lung cancer?

Question

Hello doctor,

My mom is 53 and has small-cell carcinoma of the left lung. She has been off chemotherapy for about six weeks after having a bad reaction to her last regimen. She is on a steroid taper right now and seems stable, but she gets winded with activity and has some chest discomfort.

Her latest scan showed the liver disease is about the same, maybe some tiny changes. What should we be thinking about next?

Please advise.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

Thank you so much for sharing your concern with me.

She is stable and off oxygen, which is encouraging. Those millimeter-level changes in the liver could represent pseudoprogression rather than true growth, and holding steady for six weeks off treatment in a small cell is a positive sign, given how aggressively that cancer typically progresses.

I would keep her on the drug holiday and repeat imaging in another six weeks. The more time her body has to recover from chemotherapy-related toxicity before starting the next line of treatment, the better.

When the time comes, the options include Irinotecan (Camptosar), Topotecan (Hycamtin), Temozolomide (Temodar), Lurbinectedin (Zepzelca), and Tarlatamab (Imdelltra). I would lean toward Irinotecan, as it tends to be effective against small cells, and the dosing schedule is manageable. It can cause diarrhoea, nausea, vomiting, and myelosuppression, but many patients tolerate it reasonably well. Topotecan is in the same class, tends to cause more fatigue, and has a less convenient schedule.

Temozolomide is an oral option, which is more convenient, and it also has activity against brain metastases, which is relevant in small-cell lung cancer. Lurbinectedin is generally better tolerated than Irinotecan or Topotecan, but it has not been clearly shown to be more effective; therefore, if it is not easily accessible locally, I would not prioritize it.

Tarlatamab is the newest option and appears promising, but the first two doses require close monitoring, often in an inpatient setting, and it is not yet widely available. Given these factors, I would rank it lower among the options currently available to her.

Her oncologist will ultimately make the final decision, but Irinotecan would be my first consideration when she is ready to proceed.

Hope I have addressed all of your queries and concerns. Do follow up whenever needed.

Thank you.